2023

Utilization Report
1st Qtr 2023 Utilization Report
2nd Qtr 2023 Utilization Report
3rd Qtr 2023 Utilization Report
4th Qtr 2023 Utilization Report

2022

Utilization Report
1st Qtr 2022 Utilization Report
2nd Qtr 2022 Utilization Report
3rd Qtr 2022 Utilization Report
4th Qtr 2022 Utilization Report

2021

Utilization Report
1st Qtr 2021 Utilization Report
2nd Qtr 2021 Utilization Report
3rd Qtr 2021 Utilization Report
4th Qtr 2021 Utilization Report

2020

Utilization Report
1st Qtr 2020 Utilization Report
2nd Qtr 2020 Utilization Report
3rd Qtr 2020 Utilization Report
4th Qtr 2020 Utilization Report

2019

Utilization Report
1st Qtr 2019 Utilization Report
2nd Qtr 2019 Utilization Report
3rd Qtr 2019 Utilization Report
4th Qtr 2019 Utilization Report
Beginning with the 1st quarter 2019 report, the definition was changed for the categories of Branded-Single Source Drugs, Generic-Multi Source Drugs, and the associated Generic Drug Use Percentage

2018

Utilization Report
1st Qtr 2018 Utilization Report
2nd Qtr 2018 Utilization Report
3rd Qtr 2018 Utilization Report
4th Qtr 2018 Utilization Report

2017

Utilization Report
1st Qtr 2017 Utilization Report
2nd Qtr 2017 Utilization Report
3rd Qtr 2017 Utilization Report
4th Qtr 2017 Utilization Report

2016

Utilization Report
1st Qtr 2016 Utilization Report
2nd Qtr 2016 Utilization Report
3rd Qtr 2016 Utilization Report
4th Qtr 2016 Utilization Report

2015

Utilization Report
1st Qtr 2015 Utilization Report
2nd Qtr 2015 Utilization Report
3rd Qtr 2015 Utilization Report
4th Qtr 2015 Utilization Report

2014

Utilization Report
1st Qtr 2014 Utilization Report
2nd Qtr 2014 Utilization Report
3rd Qtr 2014 Utilization Report
4th Qtr 2014 Utilization Report
In FFY 2014, the standalone Top Drug & Drug Class reports were discontinued, and the Utilization report modified and expanded. This is the new report.

2013

Top 40 Drugs   Top 30 Drug Classes   Utilization Report
1st Qtr 2013
2nd Qtr 2013
3rd Qtr 2013
4th Qtr 2013
Discontinued
  1st Qtr 2013
2nd Qtr 2013
3rd Qtr 2013
4th Qtr 2013
Discontinued
  1st Qtr 2013
2nd Qtr 2013
3rd Qtr 2013
4th Qtr 2013*
*New version
 

2012

Top 40 Drugs   Top 30 Drug Classes   Utilization Report
1st Qtr 2012
2nd Qtr 2012
3rd Qtr 2012
4th Qtr 2012
  1st Qtr 2012
2nd Qtr 2012
3rd Qtr 2012
4th Qtr 2012
  1st Qtr 2012
2nd Qtr 2012
3rd Qtr 2012
4th Qtr 2012
 

2011

Top 40 Drugs   Top 30 Drug Classes   Utilization Report
1st Qtr 2011
2nd Qtr 2011
3rd Qtr 2011
4th Qtr 2011
  1st Qtr 2011
2nd Qtr 2011
3rd Qtr 2011
4th Qtr 2011
  1st Qtr 2011
2nd Qtr 2011
3rd Qtr 2011
4th Qtr 2011
 

2010

Top 40 Drugs   Top 30 Drug Classes   Utilization Report
1st Qtr 2010
2nd Qtr 2010
3rd Qtr 2010
4th Qtr 2010
  1st Qtr 2010
2nd Qtr 2010
3rd Qtr 2010
4th Qtr 2010
  1st Qtr 2010
2nd Qtr 2010
3rd Qtr 2010
4th Qtr 2010
 

2009

Top 40 Drugs   Top 30 Drug Classes   Utilization Report
1st Qtr 2009
2nd Qtr 2009
3rd Qtr 2009
4th Qtr 2009
  1st Qtr 2009
2nd Qtr 2009
3rd Qtr 2009
4th Qtr 2009
  1st Qtr 2009
2nd Qtr 2009
3rd Qtr 2009
4th Qtr 2009
 

2008

Top 40 Drugs   Top 30 Drug Classes   Utilization Report
1st Qtr 2008
2nd Qtr 2008
3rd Qtr 2008
4th Qtr 2008
  1st Qtr 2008
2nd Qtr 2008
3rd Qtr 2008
4th Qtr 2008
  2008
 

2007

Top 40 Drugs   Top 30 Drug Classes   Utilization Report
1st Qtr 2007
2nd Qtr 2007
3rd Qtr 2007
4th Qtr 2007
  1st Qtr 2007
2nd Qtr 2007
3rd Qtr 2007
4th Qtr 2007
  2007
 

2006

Top 40 Drugs   Top 30 Drug Classes   Utilization Report
1st Qtr 2006
2nd Qtr 2006
3rd Qtr 2006
4th Qtr 2006
  1st Qtr 2006
2nd Qtr 2006
3rd Qtr 2006
4th Qtr 2006
  2006
 

2005

Top 40 Drugs   Top 30 Drug Classes   Utilization Report
1st Qtr 2005
2nd Qtr 2005
3rd Qtr 2005
4th Qtr 2005
  1st Qtr 2005
2nd Qtr 2005
3rd Qtr 2005
4th Qtr 2005
  2005
 

Disclaimer: The information contained on our Web site and news list has been prepared in good faith to provide accurate and impartial information to OMAP providers. Clinical recommendations are based on published, peer-reviewed medical literature. Although every attempt has been made to ensure that the information contained herein is timely and accurate, users should consult all available sources of drug information before making decisions regarding patient care. This information is advisory only and is not intended to replace FDA-approved labeling information, or sound clinical judgment, in the delivery of health care services. Please also note that the prescribing trends provided are highly dependent on time and method of database query. The user of this information assumes entire risk.